moneyheap
SOLV · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Solventum Corporation (SOLV) stock moving?
Solventum beat Q3 2026 estimates, with adjusted EPS of $1.45 versus $1.35 expected and sales of $1.949B versus $1.935B, and raised FY2026 adjusted EPS guidance to $7.20-$7.30 from $7.10-$7.20, above the $7.18 consensus. The stock rose 5.4% to $89.35 on Nov 4 on 2.17M shares, before the Nov 5 release. It then closed at $87.18 on Nov 5 despite the beat, reversing from an intraday high of $90.50. Shares rebounded to $90.38 on Nov 6 on 3.17M shares, the highest volume in the window, after Piper Sandler reiterated Overweight with a $110 target and Wells Fargo raised its target to $95 while keeping Equal-Weight. The stock has held around $89-90 since, closing at $90.08 on Nov 10, up from an 80.76 low on Oct 30. A collaboration with Ahlstrom on controlled-bioburden release paper (Nov 9) adds little financial weight. Risks include the stock trading near Wells Fargo's $95 target, the Nov 5 reversal showing the beat was partly priced in, and the absence of 10-Q or transcript detail in this data.
News behind the analysis
- Solventum Reports Third Quarter 2026 Financial ResultsSolventum reported Q3 2026 results that exceeded analyst expectations for both revenue and adjusted EPS.
- Solventum Raises FY2026 Adj EPS Guidance from $7.10-$7.20 to $7.20-$7.30 vs $7.18 EstSolventum raised its FY2026 adjusted EPS guidance to $7.20-$7.30, above the $7.18 consensus estimate.
- Solventum Q3 Adj. EPS $1.45 Beats $1.35 Estimate, Sales $1.949B Beat $1.935B EstimateQ3 adjusted EPS of $1.45 beat the $1.35 estimate, and sales of $1.949B beat the $1.935B estimate.
- Solventum Q3 2026 Earnings Call TranscriptTranscript of the company's third-quarter 2026 earnings call, held the same day as the results release.
- Wells Fargo and Piper Sandler Adjust Price Targets on SolventumWells Fargo and Piper Sandler updated their price targets on Solventum following the earnings report.
- Piper Sandler Reiterates Overweight on Solventum, Raises Price Target to $110Piper Sandler reiterated its Overweight rating and raised its price target to $110.
- Wells Fargo Maintains Equal-Weight on Solventum, Raises Price Target to $95Wells Fargo kept its Equal-Weight rating and raised its price target to $95.
- Ahlstrom Collaborates with Solventum on Controlled-Bioburden Release PaperAhlstrom entered a collaboration with Solventum to develop controlled-bioburden release paper for stringent healthcare uses.
About Solventum Corporation
Solventum is a medical-products company based in Eagan, Minnesota. 3M spun it off in April 2024, and it sells wound care, surgical supplies, dental products and health-information software. It is in the middle of a multi-year overhaul to stand on its own, and in August 2026 it announced plans to separate its Health Information Systems business, either by spinning it off or selling it, so it can focus on medical technology.
How it makes money
It sells products and software to hospitals, clinics and dentists, bringing in roughly $8 billion a year (approximate). MedSurg is the largest segment, at about two-thirds of sales: wound care such as negative-pressure therapy, IV site and infection-prevention products, and sterilization. Dental Solutions sells restorative and orthodontic products, at roughly a fifth of sales. Health Information Systems sells clinical coding, documentation and revenue-cycle software, including AI-assisted coding, and is the part being separated. A smaller Purification & Filtration business was sold to Thermo Fisher.
What usually moves SOLV
- Organic sales growth and margin progress from its cost-cutting program
- Progress and proceeds from separating Health Information Systems
- Problems from leaving 3M's systems, including disruption from switching to a new business-management (ERP) system
- Litigation costs, tariffs and raw-material terms in its supply deal with 3M
- Hospital procedure volumes and dental demand